Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medical procedure
|
| gptkbp:administeredBy |
gptkb:physician
|
| gptkbp:approvedBy |
gptkb:FDA
1989 |
| gptkbp:brand |
gptkb:Botox
gptkb:Dysport gptkb:Jeuveau gptkb:Xeomin |
| gptkbp:commonIn |
neurology
ophthalmology cosmetic dermatology |
| gptkbp:contraindication |
infection at injection site
allergy to botulinum toxin |
| gptkbp:discoveredBy |
gptkb:Allergan
|
| gptkbp:effect |
muscle relaxation
3-6 months reduced gland activity |
| https://www.w3.org/2000/01/rdf-schema#label |
Botox Injection
|
| gptkbp:mechanismOfAction |
blocks acetylcholine release
|
| gptkbp:routeOfAdministration |
intramuscular
intradermal |
| gptkbp:sideEffect |
headache
pain at injection site bruising drooping eyelid |
| gptkbp:usedFor |
overactive bladder
muscle spasticity wrinkle reduction chronic migraine treatment hyperhidrosis treatment |
| gptkbp:usedSubstances |
Botulinum toxin type A
|
| gptkbp:bfsParent |
gptkb:Angelina_Love
|
| gptkbp:bfsLayer |
6
|